Microba Life Sciences Limited (ASX:MAP)
Australia · Delayed Price · Currency is AUD 0.0530
0.00 (0.00%)
Sep 17, 2026, 9:59 AM AEST
Microba Life Sciences Income Statement
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
| 14.76 | 15.67 | 12.09 | 5.42 | 4.69 | |
Revenue Growth | -5.81% | 29.60% | 123.06% | 15.60% | 25.62% |
Cost of Revenue | 7.73 | 8.23 | 6.18 | 2.74 | 2.32 |
Gross Profit | 7.03 | 7.44 | 5.91 | 2.68 | 2.37 |
Selling, General & Admin | 19.54 | 22.52 | 16.01 | 10.18 | 10.27 |
Research & Development | 0.42 | 2.01 | 10.84 | 9.34 | 5.38 |
Other Operating Expenses | 2.96 | 3.09 | 2.03 | 1.75 | 1.44 |
Operating Expenses | 27.33 | 32.05 | 31.74 | 22.91 | 18.64 |
Operating Income | -20.3 | -24.61 | -25.84 | -20.23 | -16.27 |
Interest Expense | -0.24 | -0.18 | -0.07 | -0.06 | -0.06 |
Interest & Investment Income | 0.32 | 0.58 | 1 | 0.88 | 0.05 |
Currency Exchange Gain (Loss) | -1.51 | 1.76 | 0.1 | 0.37 | 0.49 |
Other Non Operating Income (Expenses) | 1.55 | 2.93 | 5.82 | 6.37 | 4.32 |
EBT Excluding Unusual Items | -20.19 | -19.52 | -18.98 | -12.67 | -11.46 |
Merger & Restructuring Charges | - | - | -1.01 | - | - |
Gain (Loss) on Sale of Assets | -0.1 | - | - | - | - |
Asset Writedown | -0.75 | - | - | - | - |
Other Unusual Items | 0.04 | 4.47 | - | - | - |
Pretax Income | -20.98 | -15.05 | -19.99 | -12.67 | -11.46 |
Income Tax Expense | -0.26 | -0.11 | -0.05 | 0.01 | 0.01 |
Net Income | -20.72 | -14.94 | -19.94 | -12.68 | -11.47 |
Net Income to Common | -20.72 | -14.94 | -19.94 | -12.68 | -11.47 |
Net Income Growth | - | - | - | - | - |
Shares Outstanding (Basic) | 601 | 448 | 410 | 314 | 223 |
Shares Outstanding (Diluted) | 601 | 448 | 410 | 314 | 223 |
Shares Change | 33.95% | 9.40% | 30.42% | 40.87% | 21.61% |
EPS (Basic) | -0.03 | -0.03 | -0.05 | -0.04 | -0.05 |
EPS (Diluted) | -0.03 | -0.03 | -0.05 | -0.04 | -0.05 |
EPS Growth | - | - | - | - | - |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Free Cash Flow | -12.61 | -12.34 | -17.05 | -12.94 | -12.08 |
Free Cash Flow Per Share | -0.02 | -0.03 | -0.04 | -0.04 | -0.05 |
Gross Margin | 47.61% | 47.49% | 48.84% | 49.41% | 50.46% |
Operating Margin | -137.58% | -157.05% | -213.71% | -373.24% | -347.05% |
Profit Margin | -140.40% | -95.34% | -164.92% | -233.95% | -244.64% |
Free Cash Flow Margin | -85.45% | -78.75% | -141.06% | -238.82% | -257.75% |
EBITDA | -18.66 | -22.47 | -23.67 | -19.09 | -15.56 |
EBITDA Margin | -126.40% | -143.43% | -195.80% | - | - |
D&A For EBITDA | 1.65 | 2.13 | 2.16 | 1.14 | 0.72 |
EBIT | -20.3 | -24.61 | -25.84 | -20.23 | -16.27 |
EBIT Margin | -137.58% | -157.05% | -213.71% | - | - |